Legis Daily

Mandating Exclusive Review of Individual Treatments (MERIT) Act

USA117th CongressHR-9127| House 
| Updated: 10/5/2022
Vern Buchanan

Vern Buchanan

Republican Representative

Florida

Cosponsors (8)
Adrian Smith (Republican)Neal P. Dunn (Republican)Mariannette Miller-Meeks (Republican)Maria Elvira Salazar (Republican)A. Drew Ferguson (Republican)John H. Rutherford (Republican)Brian K. Fitzpatrick (Republican)Nanette Diaz Barragán (Democratic)

Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Mandating Exclusive Review of Individual Treatments (MERIT) Act This bill specifies that coverage determinations for drugs and biologics under Medicare must be made with respect to each drug or biologic, rather than with respect to a class of drugs or biologics.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Oct 4, 2022
Introduced in House
Oct 4, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 5, 2022
Referred to the Subcommittee on Health.
  • October 4, 2022
    Introduced in House
  • October 4, 2022
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • October 5, 2022
    Referred to the Subcommittee on Health.

Health

Medical researchMedicarePrescription drugs

Mandating Exclusive Review of Individual Treatments (MERIT) Act

USA117th CongressHR-9127| House 
| Updated: 10/5/2022
Mandating Exclusive Review of Individual Treatments (MERIT) Act This bill specifies that coverage determinations for drugs and biologics under Medicare must be made with respect to each drug or biologic, rather than with respect to a class of drugs or biologics.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Oct 4, 2022
Introduced in House
Oct 4, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 5, 2022
Referred to the Subcommittee on Health.
  • October 4, 2022
    Introduced in House
  • October 4, 2022
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • October 5, 2022
    Referred to the Subcommittee on Health.
Vern Buchanan

Vern Buchanan

Republican Representative

Florida

Cosponsors (8)
Adrian Smith (Republican)Neal P. Dunn (Republican)Mariannette Miller-Meeks (Republican)Maria Elvira Salazar (Republican)A. Drew Ferguson (Republican)John H. Rutherford (Republican)Brian K. Fitzpatrick (Republican)Nanette Diaz Barragán (Democratic)

Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Medical researchMedicarePrescription drugs